The deal includes a non-tradeable CVR that pays $1.00/sh for each of three contingencies (i.e. $3.00/sh maximum). The nominal deal value (excluding the CVR) is $487M.
AKUS is pursuing gene therapy for hearing conditions. The buyout price is 26% below AKUS’s 2020 IPO price of $17.00 (#msg-156532797).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.